RON belongs to the c-MET family of
receptor tyrosine kinases. As its well-known family member MET, RON and its
ligand macrophage-stimulating protein have been implicated in the progression and
metastasis of
tumors and have been shown to be overexpressed in
cancer. We generated and tested a large number of human
monoclonal antibodies (mAbs) against human RON. Our screening yielded three high-affinity
antibodies that efficiently block
ligand-dependent intracellular AKT and MAPK signaling. This effect correlates with the strong reduction of
ligand-activated migration of T47D
breast cancer cell line. By cross-competition experiments, we showed that the antagonistic
antibodies fall into three distinct
epitope regions of the RON extracellular Sema domain. Notably, no inhibition of
tumor growth was observed in different epithelial
tumor xenografts in nude mice with any of the
antibodies. These results suggest that distinct properties beside
ligand antagonism are required for anti-RON mAbs to exert antitumor effects in vivo.